Background-Estradiol activates endothelial nitric oxide synthase (eNOS) by mechanisms that involve estrogen receptor-␣ (ER␣), protein kinase B/Akt, mitogen-activated protein kinases, and heat shock protein 90 (HSP90). Recently, AMP-activated protein kinase (AMPK), an enzyme that plays a crucial role in cellular adaptation to metabolic stress, has been implicated in physiological eNOS activation by the hormones adiponectin and insulin. We therefore investigated whether AMPK is activated by estradiol in endothelial cells and plays a role in estradiol-induced eNOS activation. Methods and Results-Porcine aortic endothelial cells exhibited time-and concentration-dependent AMPK activation as determined by phosphorylation of AMPK and its downstream target acetyl coenzyme A carboxylase in response to estradiol (1 nmol/L to 10 mol/L, 1 to 30 minutes). AMPK activation by estradiol was independent of both AMP levels and ER␣ but required estradiol conversion to its catechol metabolites. Estradiol treatment increased eNOS catalytic activity, an effect that was largely reversed when endothelial cells were infected with an AMPK dominant-negative adenovirus. However, inhibition of AMPK did not alter estradiol-induced eNOS phosphorylation at serine 1177 or threonine 495 but decreased eNOS interaction with HSP90. Consistent with this observation, blood vessels from ␣ 1 -AMPK-null mice exhibited defective eNOS-mediated NO production in response to estradiol. Conclusions-Taken together, these data indicate that AMPK activity is essential for estradiol-induced eNOS activation via the promotion of eNOS interaction with HSP90. These data point to a novel role for AMPK in modulating endothelial cell NO bioactivity and HSP90 function. 
T he acute administration of estradiol leads to a rapid increase in coronary blood flow 1 that is now known to result from activation of the endothelial isoform of nitric oxide synthase (eNOS). 2 Although endothelial cells express membrane-associated estrogen receptors (ERs) of both ␣-and ␤-isoforms, 3 only the ␣-isoform mediates eNOS activation. 2 Ligand engagement of ER␣ initiates its association with the p85␣ subunit of phosphoinositol 3-kinase and c-Src, leading to Akt activation. 4, 5 This event promotes eNOS phosphorylation at serine 1177, 6 a key event that stimulates enzyme activation 7, 8 and enhances its sensitivity to calcium. 9 The entire process of ER␣-mediated eNOS activation also involves the mitogen-activated protein kinase (MAPK) pathway, as MAPK/extracellular signal-regulated kinase (ERK) inhibition effectively attenuates the effects of estradiol. 2 Although the mechanism for this observation is not clear, MAPK has been implicated in ER␣ translocation among cellular compartments, 10 and ER␣ movement into caveolae may be involved in eNOS activation. 11 These data underscore the pleiotropic effects of ER␣ in modulating endothelial cell NO bioactivity.
Estradiol also promotes the association of eNOS with heat shock protein 90 (HSP90), 12 although the precise mechanism(s) involved in this process is not yet clear. Nevertheless, HSP90 is clearly required for maximal eNOS activation, 13 and this chaperone exhibits a predilection for proteins involved in signal transduction, including hormone receptors. 14 Indeed, HSP90 has been found in association with the ER 15 and is implicated in steroid receptor action. 16 Thus, there is precedent for involvement of HSP90 in hormone receptor responses.
As its name suggests, HSP90 is also part of the cellular response to environmental stress. For example, hypoxia, oxidative stress, osmotic shock, and arsenic are all known to result in upregulation of HSP90 protein and chaperone activity. 14 Among other cellular stress responses, activation of AMP-dependent protein kinase (AMPK) has recently garnered considerable interest. This enzyme is activated in response to both metabolic and oxidative insults and is also a key regulator of cellular energy metabolism. 17 In the present study, we sought to determine whether estrogen activates AMPK and examine the implications of AMPK for estradiolmediated eNOS activation.
Methods

Materials
Cell culture reagents were obtained from Invitrogen, and compound C was a kind gift from Merck Research Laboratories (Piscataway, NJ). We obtained LY294002, 4-amino-5-(4-chlorophenyl)-7-(tbutyl)pyrazolo [3,4-D] pyrimidine (PP2), bisindolylmaleimide, PD98059, SB202190, and 17␤-estradiol from Calbiochem. The estradiol metabolites 2-hydroxyestradiol and 2-methoxyestradiol were purchased from Steraloids. The ER antagonist ICI 182,780 was obtained from Tocris. Polyclonal antibodies against phospho-AMPK (Thr-172), ␣-AMPK, phosphoacetyl coenzyme A carboxylase (ACC) (Ser-79), and phospho-Akt (Ser-473) were from Cell Signaling Technology. Antibodies against ACC, ␣ 1 -AMPK, ␣ 2 -AMPK, phospho-eNOS (Ser-1177 or Thr-495), HSP90, and the specific AMPK target peptide HMRSAMSGLHLVKRR (SAMS peptide) were from Upstate Biotechnology. The monoclonal eNOS antibody was from BD Biosciences, and the monoclonal ER␣ antibody was from NeoMarkers. We obtained [
32 P]ATP (250 Ci, 10 mCi/mL) and [ 3 H]-L-citrulline (1 mCi/mL) from Perkin Elmer Life Sciences. The ␣ 1 -AMPK-null mice were kindly provided by Dr B. Viollet (Institut Cochin, Paris, France) and have been described. 18, 19 All other reagents were from Sigma.
Adenovirus Transfection
A dominant-negative ␣ 2 -AMPK mutant-expressing adenovirus that is known to inhibit basal and stimulated AMPK activity 20 was obtained from Dr Morris J. Birnbaum, University of Pennsylvania. Cells were infected at a multiplicity of infection of 50 as described, 21 and a ␤-galactosidase (LacZ)-expressing adenovirus (50 multiplicity of infection) was used as a control.
Cell Culture
Porcine aortic endothelial cells (PAECs) were harvested from juvenile male pigs and cultured on fibronectin-coated tissue-culture flasks in M199 supplemented with 20% fetal bovine serum, 50 g/mL heparin sulfate, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin. Before all experiments with estrogens, cells were cultured for at least 12 hours in phenol-free medium (Opti-MEM, Invitrogen) supplemented with 1% charcoal-stripped fetal bovine serum (Biomeda). Confluent cells on 6-well plates were used between passages 3 and 9. Before all treatments, endothelial cells were washed in HEPES-buffered physiological salt solution 
Cellular ATP Content and AMPK Activity
For determination of intracellular ATP levels, cells were washed twice with PSS and lysed with 250 L of ATP-releasing agent (Bioluminescent Somatic Cell Assay Kit, Sigma). Aliquots of the cell lysates were analyzed by a luciferase-catalyzed reaction of ATP with luciferin. The product, adenyl-luciferin, causes light emission by its reaction with ambient O 2 . Luminescence was recorded every 10 seconds for 1 minute in a Turner Designs luminometer. Determination of AMPK catalytic activity in endothelial cells was performed by incorporation of radioactively labeled 32 P into the specific AMPK target sequence HMRSAMSGLHLVKRR (SAMS peptide) as described previously. 22 
Determination of eNOS Catalytic Activity
Immunoblotting
After various treatments, cells were washed twice with cold PSS and lysed in 100 L of loading buffer containing 50 mmol/L Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate, 200 mmol/L dithiothreitol, 20% glycerol, and 0.1% bromophenol blue. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 7.5% to 12% gels, transferred to a nitrocellulose membrane, and incubated with the primary antibody overnight (1:1000). After washing and addition of the secondary antibody, protein bands were visualized with ECL reagent (Amersham Biosciences).
Reverse Transcription-Polymerase Chain Reaction
Human aortic endothelial cells in 100-mm dishes were washed in phosphate-buffered saline and subjected to RNA isolation. After RNA extraction, reverse transcription-polymerase chain reaction was performed with forward (sense) and reverse (antisense) primers. Nucleotide sequences for human AMPK isoforms were designed as follows: ␣ 1 sense, 5Ј33Ј-GAG CCT TGA TGT GGT AGG and ␣ 1 antisense, 5Ј33Ј-GGA AGG GTT CCA CAT AAT; ␣ 2 sense, 5Ј33Ј-TCT GGA GGT GAA TTA TTT and ␣ 2 antisense, 5Ј33Ј-CCA TTC ATG CTC TCT TAT; ␤ 1 sense, 5Ј33Ј-CAA CGG TGT TTC GAT GGA and ␤ 1 antisense, 5Ј33Ј-AGG TGG TGA CGT ACT TCT; ␤ 2 sense, 5Ј33Ј-GAT TTG GAG GAC TCC GTA and ␤ 2 antisense, 5Ј33Ј-AAG GAC CAT CAC ACT GTC; ␥ 1 sense, 5Ј33Ј-ATG AAG TCT CAT CGC TGC and ␥ 1 antisense, 5Ј33Ј-CCA ATC TGT AGC TCT TCC; ␥ 2 sense, 5Ј33Ј-CAT GCG ATT CAT GAG GTC and ␥ 2 antisense, 5Ј33Ј-ATT CCA AGC TCA TCC AGG; ␥ 3 sense, 5Ј33Ј-TTG AGA TGG ACA AGG CAG and ␥ 3 antisense, 5Ј33Ј: CAG AGC AAA GAA GGC CTT.
Blood Vessel NO Bioactivity
Aortas were harvested from 10-to 12-week-old mice, cleaned of excess tissue, and cut into equal segments. All aortas were opened and incubated for 15 minutes in oxygenated Krebs'-HEPES solution with 0.1 mmol/L isobutylmethylxanthine at 37°C as described 21 and then stimulated with either 100 nmol/L estradiol or sodium(Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA-NONOate) for 5 minutes. When required, nitro-L-arginine methyl ester (0.5 mmol/L) was also added to the buffer 15 minutes before stimulation. Vessels were immediately snap-frozen in LN 2 and homogenized in ice-cold 5% trichloroacetic acid containing 0.5 mmol/L isobutylmethylxanthine. Cyclic GMP levels were measured in vessel extracts with a commercially available immunoassay (Cayman Chemical Co), and results were expressed as picomoles cGMP per milligram of trichloroacetic acid-precipitable protein solubilized with 1 mol/L NaOH.
Statistical Analysis
All immunoblots are representative of 3 or 4 independent experiments. Numerical data are presented as meanϮSEM. Comparisons among treatment groups were performed with 1-way ANOVA and an appropriate post hoc Dunnett or Student-Newman-Keuls comparison. Statistical significance was accepted when the null hypothesis was rejected at PϽ0.05.
Results
Estradiol Activates AMPK in Endothelial Cells
Treatment of PAECs with estradiol resulted in a time-and concentration-dependent activation of AMPK, as monitored by phosphorylation of AMPK and its downstream target ACC ( Figure 1A and 1B) . Similar results were obtained when AMPK activity was measured by 32 P incorporation into the AMPK-specific SAMS peptide ( Figure 1C) . Thus, estradiol activates AMPK over a physiological concentration range.
AMPK Activation by Estradiol Is Independent of AMP
To determine whether estradiol-induced AMPK activation depends on AMP, we used the adenylate kinase inhibitor 5-iodotubercidin to block intracellular AMP formation from ADP. 23 We found that 5-iodotubercidin had no effect on PAEC AMPK activation (Figure 2A and 2B) . As one might predict, estradiol also had no effect on cellular ATP levels that would ultimately result in AMP formation ( Figure 2C ). Thus, estradiol activates AMPK independent of AMP formation.
AMPK Activation by Estradiol Is Independent of
ERs and Does Not Involve ERK, p38 MAPK, Phosphoinositol 3-Kinase, Src, or Protein Kinase C Because functional ERs are required for nongenomic effects of estradiol, 2 we sought to determine whether ERs mediate estradiol-induced AMPK activation. Despite robust expression of ER␣ (data not shown), estradiol-induced AMPK activation was not inhibited by the ER antagonist ICI182,780 ( Figure 3A and 3B) . In contrast, the AMPK inhibitor, compound C, 24 potently suppressed basal and estradiol- After addition of 100 nmol/L estradiol (E 2 , 2 minutes) or vehicle, cells were lysed and either subjected to immunoblotting with antibodies against phosphorylated ACC and AMPK (A) or used for AMPK activity assay (B) as described in Methods. C, PAECs were treated with 100 nmol/L estradiol for indicated times and lysed, and lysate ATP levels were determined as described in Methods. Immunoblots are representative of 3 independent experiments, and cellular ATP levels represent meanϮSEM of 3 independent experiments. *PϽ0.05 vs without estradiol by paired t test or 1-way ANOVA as appropriate.
stimulated AMPK activity in endothelial cells ( Figure 3C and 3D). These data indicate that estradiol activates AMPK independent of ERs.
To examine possible upstream signals that mediate AMPK activation by estradiol, we used inhibitors of several signaling pathways known to be modulated by estrogens. 2, 5, 25, 26 As shown in Figure 3E , inhibition of Src-family kinases (PP2), phosphoinositol 3-kinase (LY294002), ERK (PD98059), or protein kinase C (bisindolylmaleimide and Gö6893) had no material impact on estradiol-induced AMPK activation. These data indicate that estradiol must activate AMPK by mechanisms distinct from signals associated with ER activation.
Estradiol-Induced AMPK Activation Is Mediated by Catechol Estradiol Metabolites
Previous studies suggest that estradiol conversion to 2-hydroxyestradiol and 2-methoxyestradiol is involved in its antimitogenic activity in smooth muscle cells. 27 These estradiol metabolites act largely in a receptor-independent manner, as they have only limited affinity for ERs. 27 Estradiol hydroxylation at C-2 and C-4 via the cytochrome p450 class of enzymes yields the catechol estradiols 2-and 4-hydroxyestradiol that, in turn, may be converted into methoxyestradiols via catechol-O-methyltransferase (for review, see Dubey et al 27 ). We found that inhibition of hydroxyestradiol formation with the cytochrome p450 inhibitor 1-aminobenzotriazole attenuated estradiol-mediated AMPK activation ( Figure 4A ). In contrast, inhibition of Figure 1 . B, PAECs in PSS were treated with either 100 nmol/L 2-hydroxyestradiol (2-HE 2 ) or 2-methoxyestradiol (2-ME 2 ) for 2 minutes. Cells were then lysed and probed for ACC or AMPK phosphorylation as in A. Immunoblots are representative of 3 independent experiments. hydroxyestradiol conversion to their methoxy counterparts with the catechol-O-methyltransferase inhibitor Ro 41-0960 enhanced estradiol-induced AMPK activation ( Figure 4A ), suggesting that hydroxyestradiols mediate AMPK activation by estradiol. Consistent with this notion, 2-hydroxyestradiol significantly increased AMPK activity, whereas 2-methoxyestradiol was less effective ( Figure 4B ). Taken together, these results suggest that estradiol-induced AMPK activation is mediated by its conversion to hydroxyestradiols.
Estradiol-Induced eNOS Activation Requires AMPK
We next investigated the role of AMPK in estradiol-induced eNOS activation. Estradiol induced dose-dependent eNOS activation, as manifested by enhanced [ 3 H]-L-citrulline production, eNOS Ser-1177 phosphorylation, and eNOS association with HSP90 ( Figure 5A and 5B). We also found that AMPK exists in a complex with eNOS under basal conditions, and this did not change as a function of estradiol stimulation ( Figure 5B ). Inhibition of AMPK activity with either a dominant-negative AMPK mutant ( Figure 5C ) or compound C abrogated estradiol-mediated eNOS activation ( Figure 5D ). Thus, estradiol-mediated eNOS activation requires the catalytic activity of AMPK.
Estradiol-Induced HSP90 Association With eNOS Requires AMPK
To determine the mechanism involved in AMPK-mediated eNOS activation, we examined eNOS phosphorylation status and HSP90 binding in response to estradiol. As expected, estradiol stimulated Akt, resulting in eNOS Ser-1177 phosphorylation ( Figure 6 ). This process was not altered by either pharmacological or molecular inhibition of AMPK ( Figure  6 ). In contrast, AMPK inhibition significantly attenuated eNOS association with HSP90 ( Figure 6 ). These data implicate AMPK in the dynamic modulation of eNOS activity by HSP90.
Estradiol-Induced eNOS Activation In Vivo Requires ␣ 1 -AMPK
We found in preliminary experiments with reverse transcription-polymerase chain reaction and immunoblotting that endothelial cells predominantly express the ␣ 1 , ␤ 1 , and ␥ 2 isoforms of AMPK (data not shown). Accordingly, to determine the physiological significance of our in vitro results, we examined estradiol-mediated eNOS activation in intact aortic segments from wild-type and ␣ 1 -AMPK-null mice. Wildtype mice exhibited estradiol-mediated eNOS activation manifested as an increase in aortic cGMP content (PϽ0.05, nϭ4) that was inhibited by 500 mol/L nitro-L-arginine methyl ester ( Figure 7C ). In contrast, ␣ 1 -AMPK-null mice demonstrated no significant estradiol-mediated eNOS activation (Pϭ0.17, nϭ4) despite DEA-NONOate-induced cGMP accumulation that was comparable to that of wild-type mice ( Figure 7C ). These data indicate that estradiol-mediated eNOS activation in vivo requires ␣ 1 -AMPK.
Discussion
The principal finding of our study is that AMPK is activated by estradiol and appears required for estradiol-mediated eNOS activation. This stimulation of AMPK did not depend on ERs, because it was insensitive to the ER antagonist ICI182,780. Instead, AMPK activation was related to the metabolism of estradiol to hydroxyestradiol. We also found that activation of AMPK was required for HSP90 association with eNOS, a well-known requirement for optimal eNOSmediated NO production. 13, 28 In contrast, estradiol-mediated Akt activation was not dependent on AMPK catalytic activity, suggesting that estrogen promotes eNOS activation through 2 distinct, yet complementary, pathways (Figure 8) .
Common downstream targets of AMPK include key enzymes of glucose and lipid metabolism, 29, 30 and AMPK activation tends to suspend energy-consuming pathways and stimulate energy production. 17 These properties of AMPK are consistent with its known role as an adaptation to metabolic stress, and others have speculated that this enzyme may be part of a generalized cellular stress response. 17 It is also known that AMPK may be activated in response to hormones such as adiponectin 31 and leptin, 32 which are known to modulate fatty acid oxidation. We now add estradiol to the known hormonal stimuli that lead to AMPK activation. At first glance, this link between estradiol and AMPK may seem incongruous, as estrogen does not have an established role in the control of cellular energy status. However, recent studies with the aromatase-knockout mouse indicate that estrogen may have important implications for fatty acid oxidation. Animals lacking aromatase are unable to synthesize endogenous estradiol, and they exhibit hepatic steatosis 33 and increased adiposity 34 owing to impaired fatty acid oxidation. Because fatty acid oxidation is regulated in part through the action of AMPK, 17 it is tempting to speculate that impaired fatty acid oxidation in aromatase deficiency is related to our observations that estradiol activates AMPK at physiologically relevant concentrations. The precise contribution(s) of estradiol-mediated AMPK activation, however, will need to be investigated in future studies. Activation of Akt is associated with phosphorylation of eNOS on Ser-1177. Concurrently, catechol conversion of estradiol produces activation of AMPK that enhances AMPK association with eNOS. Combined pathways afford maximal eNOS-mediated NO production through both phosphorylation and enzyme association with HSP90.
